Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    GT Biopharma Inc.

    NASDAQ: GTBP · Real-Time Price · USD
    2.84
    0.02 (0.71%)
    At close: Jun 13, 2025, 3:59 PM
    2.85
    0.33%
    After-hours: Jun 13, 2025, 07:52 PM EDT

    GT Biopharma Statistics

    Share Statistics

    GT Biopharma has 2.59M shares outstanding. The number of shares has increased by 17.61% in one year.

    Shares Outstanding

    n/a
    		 2.59M

    Shares Change (YoY)

    n/a
    		 17.61%

    Shares Change (QoQ)

    n/a
    		 13.52%

    Owned by Institutions (%)

    n/a
    		 65.47%

    Shares Floating

    n/a
    		 2.05M

    Failed to Deliver (FTD) Shares

    n/a
    		 635

    FTD / Avg. Volume

    n/a
    		 1.3%

    Short Selling Information

    The latest short interest is 151.78K, so 5.87% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 151.78K

    Short % of Shares Out

    n/a
    		 5.87%

    Short % of Float

    n/a
    		 5.96%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -0.44 and the forward PE ratio is -2.77. GT Biopharma's PEG ratio is -0.02.

    PE Ratio

    n/a
    		 -0.44

    Forward PE

    n/a
    		 -2.77

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 0.4

    PB Ratio

    n/a
    		 -3.47

    P/FCF Ratio

    n/a
    		 -0.45

    PEG Ratio

    n/a
    		 -0.02
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for GT Biopharma.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 0.72, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 0.72

    Quick Ratio

    n/a
    		 0.72

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-13,162,000

    Employee Count

    n/a
    		 1

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -1.73% in the last 52 weeks. The beta is 1.39, so GT Biopharma's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.39

    52-Week Price Change

    n/a
    		 -1.73%

    50-Day Moving Average

    n/a
    		 2.46

    200-Day Moving Average

    n/a
    		 2.46

    Relative Strength Index (RSI)

    n/a
    		 55.65

    Average Volume (20 Days)

    n/a
    		 48,955

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -14.36M

    Net Income

    n/a
    		 -13.16M

    EBITDA

    n/a
    		 -13.16M

    EBIT

    n/a
    		 -13.16M

    Earnings Per Share (EPS)

    n/a
    		 -6.94
    Full Income Statement

    Balance Sheet

    The company has 3.95M in cash and 0 in debt, giving a net cash position of 3.95M.

    Cash & Cash Equivalents

    n/a
    		 3.95M

    Total Debt

    n/a
    		 n/a

    Net Cash

    n/a
    		 n/a

    Retained Earnings

    n/a
    		 -695.23M

    Total Assets

    n/a
    		 4.23M

    Working Capital

    n/a
    		 -1.67M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -12.9M and capital expenditures 0, giving a free cash flow of -12.9M.

    Operating Cash Flow

    n/a
    		 -12.9M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -12.9M

    FCF Per Share

    n/a
    		 -6.8
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    GTBP does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for GTBP is $11, which is 287.3% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $11

    Price Target Difference

    n/a
    		 287.3%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 1
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Feb 5, 2024. It was a backward split with a ratio of 1:30.

    Last Split Date

    n/a
    		 Feb 5, 2024

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:30

    Scores

    Altman Z-Score

    n/a
    		 -240.43

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist